Henry Meds vs Noom

Neither Henry Meds nor Noom has an FDA warning letter on record. On compounded semaglutide injection, Noom costs $1,416 less a year at standing rates: $179 a month against $297 a month at Henry Meds.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Henry Meds / Noom

Henry Meds logo

Henry Meds

5.6/10

Noom logo

Noom

5.8/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$249/moCompounded oral semaglutide
$179/moCompounded semaglutide injection
States
No state list published
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026

Neither Henry Meds nor Noom pays us. Links to them earn nothing. Scores: Henry Meds 5.6, Noom 5.8. How we are paid

What the record shows

  1. 01

    Neither Henry Meds nor Noom has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded semaglutide injection, Noom costs $1,416 less a year at standing rates: $179 a month against $297 a month at Henry Meds.

  4. 04

    Only Henry Meds lists a price for compounded tirzepatide injection and compounded oral semaglutide. Only Noom lists a price for brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Henry Meds

Noom

Compounded semaglutide injection

$297/mo

$3,564 a year

$179/moLower

$2,148 a year

Compounded tirzepatide injection

$349/mo

$4,188 a year

Not sold or not priced
Brand-name tirzepatide pen
Not sold or not priced

$349/mo

$4,188 a year

Compounded oral semaglutide

$249/mo

$2,988 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on monthly plans; longer plans are offered for some treatments
Not stated
Refunds
Subscription fees generally non-refundable; medication is final sale once shipped
Refunds only before a prescription is written; renewal charges are not refunded
Early-exit fee
Yes
Not stated

Read off each seller’s own pages. Henry Meds: October 30, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Henry Meds

5.6/10
  • Sells compounded tirzepatide injection and compounded oral semaglutide, which Noom does not price
  • Names no compounding pharmacy

The case for Noom

5.8/10
  • $1,416 a year less on compounded semaglutide injection
  • Sells brand-name tirzepatide pen, which Henry Meds does not price
  • Names no compounding pharmacy

Scores

Henry Meds 5.6 · Noom 5.8 out of 10. Six weighted parts.

Value25%

3.4A
vs
B
0.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

3.0A
vs
B
8.0

Trust & Safety15%

4.0A
vs
B
6.5

Accessibility10%

5.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

Henry Meds vs Noom: questions

Neither Henry Meds nor Noom has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Noom, by $1,416 a year at standing rates. Henry Meds: $297 a month, about $3,564 a year. Noom: $179 a month, about $2,148 a year.
Henry Meds states you can cancel at any time; refunds: subscription fees generally non-refundable; medication is final sale once shipped. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither Henry Meds nor Noom pays us. Links to them earn nothing. Scores: Henry Meds 5.6, Noom 5.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks